Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options. METHODS: We performed multiparameter flow cytometry on freshly isolated metastatic melanoma samples from 2 cohorts of 20 patients each prior to treatment and correlated the subsequent clinical response with the tumor immune phenotype. RESULTS: Increasing fractions of programmed cell death 1 high/cytotoxic T lymphocyte-associated protein 4 high (PD-1hiCTLA-4hi) cells within the tumor-infiltrating CD8+ T cell subset strongly correlated with response to therapy (RR) and progression-free survival (PFS). Functional analysis of these cells revealed a partially exhausted T cell phenotype. Assessment of metastatic lesions during anti-PD-1 therapy demonstrated a release of T cell exhaustion, as measured by an accumulation of highly activated CD8+ T cells within tumors, with no effect on Tregs. CONCLUSIONS: Our data suggest that the relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to anti-PD-1 therapy. This information can be used to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition. FUNDING: This work was funded by a generous gift provided by Inga-Lill and David Amoroso as well as a generous gift provided by Stephen Juelsgaard and Lori Cook.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the presence of CD8 + PD-1 hi T cells in the tumors of patients with melanoma and patients with NSCLC prior to anti-PD-1 administration was predictive of treatment response and correlated with overall survival (146, 147).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [146]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Self-citationPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Self-citationBrahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Cited by
Items 401–500 of 528
Zahiu, T., Mihu, C. M., Boşca, A. B., Mărginean, M. V., Mocan, L. P., Lupean, R.-A., Suflețel, R. T., Mihu, C., & Melincovici, C. S. (2025) · Diagnostics · doi:10.3390/diagnostics15111323 · Cited by 6
Hegyi, B., Csikó, K. G., Balatoni, T., Fröhlich, G., Bőcs, K., Tóth, E., Mohos, A., Neumark, A. R., Menyhárt, C. D., Ferrone, S., et al. (2024) · Biomolecules · doi:10.3390/biom14121609 · Cited by 2
Madsen, C. S., Makela, A. V., Maduka, C. V., Greeson, E. M., Tundo, A., Ural, E. E., Kulkarni, S. H., Zarea, A. A., Kiupel, M., Sayadi, M., et al. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00590 · Cited by 3
A strategy for uncovering germline variants altering anti-tumor CD8 T cell response
Ulaganathan, V. K., & Vasileva, M. H. (2023) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2023.01.001 · Cited by 3
Tambunlertchai, S., Geary, S. M., Naguib, Y. W., & Salem, A. K. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00824-3 · Cited by 3
Elucidating Durable Responses to Immune Checkpoint Inhibition
Rescigno, P., Aversa, C., Crespo, M., Seed, G., Lambros, M. B. K., Gürel, B., Figueiredo, I., Bianchini, D., Riisnaes, R., Pereira, R., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.06.056 · Cited by 3
The Human Tumor Microenvironment
Vano, Y. A., Giraldo, N. A., Fridman, W. H., & Sautès‐Fridman, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_2 · Cited by 5
Protocol for Creating Antibodies with Complex Fluorescence Spectra
McCarthy, M. E., Anglin, C. M., Peer, H. A., Boleman, S., Klaubert, S. R., & Birtwistle, M. R. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00220 · Cited by 3
Zaretsky, A. R., Демидов, Л. В., & Самойленко, И. В. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-9-48-63 · Cited by 4
Wang, S., Qu, X., Li, Z., Che, X., Cao, L., Yang, X., Hu, X., Xu, L., Hou, K., Fan, Y., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-968 · Cited by 2
Tumor-Infiltrating Lymphocytes, CAR-, and T-Cell Receptor-Modified T Cells in Solid Cancer Oncology
Echchannaoui, H., Legscha, K. J., & Theobald, M. (2025) · Oncology Research and Treatment · doi:10.1159/000543998 · Cited by 2
Opportunities for Discovery Using Neoadjuvant Immune Checkpoint Blockade in Melanoma
Nair, U., Rakestraw, E., Beasley, G. M., & O'Connor, M. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062427 · Cited by 2
Pre‐Encoded IFN‐I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors
Nguyen, A., Walsh, S. R., Deng, L., Chen, L., & Wan, Y. (2025) · Advanced Science · doi:10.1002/advs.202504474 · Cited by 2
Vaňková, L., Polívka, J., Křížková, V., Vokurka, S., Fiala, O., Holubová, M., Pivovarčíková, K., Třešková, I., Knížková, T., Říčař, J., et al. (2025) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2025.105016 · Cited by 2
Tenorio-Pedraza, J. M., Lippert, J., Burghaus, R., & Scheerans, C. (2023) · Translational Medicine Communications · doi:10.1186/s41231-023-00151-x · Cited by 2
Flaherty, K. R., Kucykowicz, S., Schroth, J., Traves, W., Mincham, K. T., & Finney, G. E. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad026 · Cited by 3
PD-L1 expression in pancreaticobiliary adenosquamous carcinoma: a single-institution case series
Ward, J. D., Fowler, M., Robledo-Gomez, A., Goodyear, S. M., Kardosh, A., & Sasatomi, E. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-9 · Cited by 2
Gupta, M., Stukalin, I., Meyers, D. E., Heng, D. Y. C., Monzon, J. G., Cheng, T., & Navani, V. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1385425 · Cited by 2
Lee, D. K., Park, S. R., Kim, Y. H., Lee, Y., Shin, S., Ahn, B., Lee, S. S., Lim, S. M., Kim, H. R., Cho, B. C., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2371563 · Cited by 2
GPR55 in the tumor microenvironment of pancreatic cancer controls tumorigenesis
Ristić, D., Bärnthaler, T., Gruden, E., Kienzl, M., Danner, L., Herceg, K., Sarsembayeva, A., Kargl, J., & Schicho, R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1513547 · Cited by 6
Molina-García, M., Rojas‐Lechuga, M. J., Torres, T., Crespí-Payeras, F., Bagué, J., Mateu, J., Paschalidis, N., de Souza, V. G., Podlipnik, S., Carrera, C., et al. (2025) · Cancers · doi:10.3390/cancers17122022 · Cited by 2
Biomarkers for immune therapy in melanoma
Johnson, D. B., Chon, J., Johnson, M. R., & Balko, J. M. (2018) · Seminars in Cutaneous Medicine and Surgery · doi:10.12788/j.sder.2018.019 · Cited by 2
Personalized cancer immunotherapy
Kumar, A., Weller, K. P., & Vilgelm, A. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90949-5.00012-7 · Cited by 3
Zheng, T., Yue, P., Han, T., Zhang, K., Jiang, Y., Wang, S., Jiang, L., Zhao, B., Zhang, X., & Yan, X. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4984 · Cited by 2
Zhang, S., Xiong, Y., Zheng, C., Long, J., Zhou, H., Zeng, Z., Ouyang, Y., & Tang, F. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.821678 · Cited by 2
Single-Cell RNA-Seq Reveals Naïve B cells Associated with Better Prognosis of HCCPreprint
He, J., Lin, Y., Su, X., Luo, Q., Ghazanfar, S., Yang, J. Y. H., & Han, Z. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/731935 · Cited by 2
Vignali, P., DePeaux, K., Watson, M. J., Menk, A. V., Scharping, N. E., & Delgoffe, G. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-sitc2020.0512 · Cited by 2
Intratumoral administration of mRNA-1273 vaccine delays melanoma growth in micePreprint
Boehm, D. T., Landreth, K. M., Sen-Kilic, E., Lee, K. S., Misra, B., Bobbala, S. K. R., Damron, F. H., & Liu, T. W. B. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.06.592840 · Cited by 2
Kaptein, P., Slingerland, N., van der Leun, A. M., Runderkamp, E., Wagensveld, R. A., Chin, S. M., Mors, J. R., Machuca-Ostos, M., Reißig, T. M., Moynihan, K. D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.24.676875 · Cited by 4
Ahmed, B. H., Zdyrski, C., Cheville, J. C., Rancilio, N. J., Abel, A. M., Wierson, W. A., McGill, J. L., Mochel, J. P., & Allenspach, K. (2023) · Clinical and Translational Discovery · doi:10.1002/ctd2.235 · Cited by 2
Blocking Co-inhibitory Receptors: A Promising Cancer Immunotherapy strategy
Acharya, N. (2024) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-97-5508-0_2 · Cited by 1
Crossing the blood-brain barrier: The therapeutic potential of lncRNAs in neurosurgery
Khazeni, S., & Mousavi, S. Y. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110487 · Cited by 3
Spitschak, A., Casalegno‐Garduño, R., & Pützer, B. M. (2026) · Biomarker Research · doi:10.1186/s40364-026-00925-z · Cited by 5
Karakousis, V. A., Mantalovas, S., Karakousi, V. C., Vizirianakis, I. S., Papamitsou, T., Pavlidis, L., & Kosmidis, C. S. (2026) · Cells · doi:10.3390/cells15131182 · Cited by 2
Biomarkers for Immune Checkpoint Inhibitors
Sharif, P. M., Keshavarz‐Fathi, M., & Rezaei, N. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_25 · Cited by 1
Bołkuń, Ł., Tynecka, M., Walewska, A., Bernatowicz, M., Piszcz, J. A., Cichocka, E., Wandtke, T., Czemerska, M., Wierzbowska, A., Moniuszko, M., et al. (2023) · Cancers · doi:10.3390/cancers15184487 · Cited by 1
The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers
Mustafa, S., Jansen, C. S., Jani, Y. C., Evans, S., Zhuang, T., Brown, J. T., Nazha, B., Master, V. A., & Bilen, M. A. (2024) · Biomarker Insights · doi:10.1177/11772719241254179 · Cited by 2
Вачагановна, О. Л., Эдуардовна, З. Л., Ognerubov, N. A., Kostalanova, I. V., Orlov, A. E., & Poddubnaya, I. V. (2024) · Journal of Modern Oncology · doi:10.26442/18151434.2024.2.202803 · Cited by 1
Hu, M., Fan, D., Tu, H.-F., Tsai, Y.-C., He, L., Zhou, Z., Cheng, M., Xing, D., Wang, S., Wu, A., et al. (2024) · Gene Therapy · doi:10.1038/s41434-024-00497-3 · Cited by 1
Ren, J., Wang, K., Meng, Q., Xu, C., Liu, C., Wang, Y., & Wang, G. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241308389 · Cited by 2
Zhang, J., Sun, L., Ready, N., Guo, W., & Lin, L. (2025) · Patterns · doi:10.1016/j.patter.2025.101297 · Cited by 1
Applications of biomarkers for different purposes in drug development
Halim, A. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816121-0.00002-7 · Cited by 1
Yang, Y., & Wang, Y. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.101.42 · Cited by 1
Lymphocytes T-CD8 et immunothérapie anti-tumorale : rôle et Ciblage thérapeutique
Paolini, L., Saldmann, A., & Tartour, É. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.01.018 · Cited by 4
New Melanoma Staging: Prognostic Factors
Spagnolo, F., Boutros, A., Croce, E., Tanda, E. T., Cecchi, F., & Queirolo, P. (2020) · Updates in surgery/Updates in surgery series · doi:10.1007/978-3-030-45347-3_6 · Cited by 1
Predictive Biomarkers of Melanoma
Hanly, A. M., Gibson, F. T., & Alani, R. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-82639-0_16 · Cited by 1
Yan, F., Jiang, Q., Ru, B., Fei, X.-J., Ruan, J., & Zhang, X. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i8.2497 · Cited by 1
Grandal, B., Aljehani, A., Dumas, É., Daoud, E., Jochum, F., Gougis, P., Hotton, J., Lemoine, A., Michel, S., Laas, E., et al. (2022) · Cancers · doi:10.3390/cancers14133080 · Cited by 2
Biomarkers for Cancer Immunotherapy
Ahsan, H., Islam, S. U., Ahmed, M. B., Lee, Y. S., Qayum, M., & Sonn, J. K. (2022) · Springer eBooks · doi:10.1007/978-981-16-5759-7_9 · Cited by 1
[Retracted] Computational Biology Predicts the Efficacy of Tumor Immune Checkpoint Blockade
Kang, W., Tong, Y., Zhang, W., Jian, M., Zhang, A., Ren, G., Fan, H., & Yang, J. (2022) · BioMed Research International · doi:10.1155/2022/6087751 · Cited by 1
RetractedChen, S., Yu, B., Kuo, W.-Y., Lin, Y.-B., Su, S.-Y., Lu, I.-H., & Lin, C. (2020) · Preprints.org · doi:10.20944/preprints202011.0385.v1 · Cited by 1
Use of precision methods to accelerate drug development in oncology
Coyne, G. O., Ivy, S. P., & Conley, B. A. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1311773
Highlights of the season 2016–2017 by the Spanish Melanoma Group (GEM)
On behalf of the Spanish Melanoma Group (GEM), Soria, A., Manzano, J. L., Berrocal, A., Espinosa, E., Márquez‐Rodas, I., González‐Cao, M., & Martín‐Algarra, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.37
Predictors of Response to Immune Checkpoint Blockade
Andrews, M. C., & Wargo, J. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_31
Immunobiology of the Melanoma Microenvironment
Kawakami, Y., & Riker, A. I. (2018) · Springer eBooks · doi:10.1007/978-3-319-78310-9_8
ENHANCING RADIATION SENSITIVITY IN NON-SMALL CELL LUNG CANCER
Wang, Y. (2018) · Digital Commons-TMC (Texas Medical Center)
Age, Sex, and Genetics Influence the Abundance of Infiltrating Immune Cells in Human TissuesPreprint
Marderstein, A. R., Uppal, M., Verma, A., Bhinder, B., Mezey, J. G., Clark, A. G., & Elemento, O. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/614305
Immune checkpoint blockade in glioma
Ferguson, S. D., Weathers, S.-P. S., & Heimberger, A. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813158-9.00034-7
Genetic Drivers and Clonal Heterogeneity of Lethal Breast Cancer
Siegel, M. B. (2017) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/sh0z-1n96
Mahuron, K. M., Levine, L. S., & DAUD, A. I. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08672-7
Self-citationConsiderations for cancer immunotherapy biomarker research during COVID-19
Carlisle, J. W., Jansen, C. S., Bilen, M. A., & Kissick, H. T. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0187
Fluorescent Antibody Multiplexing with Oligo-Based Combinatorial LabelingPreprint
McCarthy, M. E., Anglin, C. M., Peer, H. A., Boleman, S., Klaubert, S. R., & Birtwistle, M. R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.06.371906
Arasanz, H. (2020) · Academica-e (Universidad Pública de Navarra) · doi:10.48035/tesis/2454/41091
Immunotherapy in Cancer: Immune Checkpoint Inhibitors; Changing Oncology Treatment Paradigm
Syed, S. S. (2020) · Springer eBooks · doi:10.1007/978-981-15-9038-2_2
A new predictive biomarker enables more accurate PD-1 blockade therapy
Zhang, K., & Jiang, S. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00645-4
Zhang, R., Liu, T., Tsuchiya, N., Mashima, H., Kobayashi, T., Nakatsura, T., Ohdan, H., Endo, I., Senju, S., & Uemura, Y. (2021) · Journal of Immunology and Regenerative Medicine · doi:10.1016/j.regen.2021.100042
Algazi, A. P., Twitty, C., Tsai, K. K., Le, M. H., Pierce, R. H., Campbell, J. S., Browning, E., Hermiz, R., Canton, D., Bannavong, D., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3346978
Self-citationProteomic biomarker technology for cancer immunotherapy
Fankhauser, R. G., DePatie, N., Berryman, R., Lucero, O. M., & Kulkarni, R. P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90949-5.00007-3 · Cited by 1
Fawaz, B., Sahni, D., & Lerner, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-82639-0_15
6 Intramedullary Spinal Cord Tumors: Current Research and Potential Therapeutics
(2021) · Thieme Medical Publishers eBooks · doi:10.1055/b-0041-184166
Carlisle, J. W., Jansen, C. S., Cardenas, M. A., Soierajska, E., Reyes, A. M., Greenwald, R., del Balzo, L., Prokhnevska, N., Küçük, Ö., Carthon, B. C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-699618/v1
Daniels, G. A. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_11
Current Immunotherapy of Melanoma
Loo, K. L., Wu, C., & DAUD, A. I. (2018) · Springer eBooks · doi:10.1007/978-3-319-78310-9_35
Self-citation张, 凤. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.119580
Ma, X. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738784119.793583429
Lee, S. Y., & Bhatia, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00002-0
Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs
Agha, D. M., Rouas, R., Najar, M., Bouhtit, F., Naamane, N., Fayyad‐Kazan, H., Bron, D., Meuleman, N., Lewalle, P., & Merimi, M. (2021) · Vide Leaf, Hyderabad eBooks · doi:10.37247/imcac.1.2021.12 · Cited by 1
Tsokos, G. C. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734323237.793570389
Immunotherapy in Melanoma and Merkel Cell Cancer
Chow, M., Sangalang, E. A., Chow, C., & DAUD, A. I. (2022) · Springer eBooks · doi:10.1007/978-3-030-93084-4_67
Self-citation魏, 超. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.133714
Biomarqueurs prédictifs de la réponse à l’immunothérapie dans les mélanomes
Pourmir, I., Gey, A., Pineau, J., Lebbé, C., & Tartour, É. (2023) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.03.019
Homeostatic Dysregulation of Systemic CD8 + T Cell Compartment in Lung Cancer PatientsPreprint
Lee, S., Yun, J. S., Kim, Y. J., Kim, H.-O., Cho, H.-J., Park, C., Oh, I., & Cho, J.-H. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.27.573474
"Negative Association between Diabetes Mellitus and the Efficacy of Cancer Immunotherapy"
Sun, M. (2024) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2024.55.008726
Shi, A., Yan, M., Pang, B., Pang, L., Wang, Y., Lan, Y., Zhang, X., Xu, J., Ping, Y., & Hu, J. R. (2023) · Figshare · doi:10.6084/m9.figshare.24792276
Yang, J., Hsu, T.-H., Chen, C., Yu, J.-H., Lin, K., & Chen, Y. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100792
Zhang, S., Long, J., Hu, Z., Huang, W., Hu, W., & Zeng, Z. (2024) · Springer eBooks · doi:10.1007/978-981-97-6246-0_3
Tao, R. E., Pixley, J. N., Ahn, C., & Feldman, S. R. (2025) · Springer eBooks · doi:10.1007/978-3-031-66513-4_10
Chen, S., Yu, B., Kuo, W.-Y., Lin, Y.-B., Su, S.-Y., Chuang, W., Lu, I.-H., & Lin, C. (2025) · BMC Cancer · doi:10.1186/s12885-025-14089-w
They Contain Multitudes: The Diverse Roles of CD4+ T Cells in Cancer Immunity
Ferris, S. T., & Alspach, E. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070524-034911
Genetic and Epigenetic Indicators Predicting Response to Immune Checkpoint Inhibitors
Yang, J., Wang, B., Sun, Q., & Cai, D. (2025) · Bulletin of pioneering researches of medical and clinical science · doi:10.51847/jv5favsxwc
Macedo, R., Harle, D. W., Hoffer-Hawlik, K., Wang, X. K., McMahon-Skates, T., Matschiner, A., Belay, K., Saenger, Y. M., Izar, B., Azizi, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.10.693486
Capone, M., Fratangelo, F., Giannarelli, D., Sorrentino, C., Turiello, R., Zanotta, S., Galati, D., Madonna, G., Tuffanelli, M., Scarpato, L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11972547
Mou, W., Zhu, L., Yang, T., Lin, A., Lyu, Q., Guo, L., Liu, Z., Cheng, Q., Zhang, J., & Luo, P. (2022) · Figshare · doi:10.6084/m9.figshare.20317759
Mou, W., Zhu, L., Yang, T., Lin, A., Lyu, Q., Guo, L., Liu, Z., Cheng, Q., Zhang, J., & Luo, P. (2022) · Figshare · doi:10.6084/m9.figshare.20317771
Mou, W., Zhu, L., Yang, T., Lin, A., Lyu, Q., Guo, L., Liu, Z., Cheng, Q., Zhang, J., & Luo, P. (2022) · Figshare · doi:10.6084/m9.figshare.20317765
Shi, A., Yan, M., Pang, B., Pang, L., Wang, Y., Lan, Y., Zhang, X., Xu, J., Ping, Y., & Hu, J. (2024) · Figshare · doi:10.6084/m9.figshare.24792441
Mou, W., Zhu, L., Yang, T., Lin, A., Lyu, Q., Guo, L., Liu, Z., Cheng, Q., Zhang, J., & Luo, P. (2022) · Figshare · doi:10.6084/m9.figshare.20317762
Tenorio-Pedraza, J. M., Lippert, J., Burghaus, R., & Scheerans, C. (2023) · Figshare · doi:10.6084/m9.figshare.23961998
Capone, M., Fratangelo, F., Giannarelli, D., Sorrentino, C., Turiello, R., Zanotta, S., Galati, D., Madonna, G., Tuffanelli, M., Scarpato, L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.11972556
Mou, W., Zhu, L., Yang, T., Lin, A., Lyu, Q., Guo, L., Liu, Z., Cheng, Q., Zhang, J., & Luo, P. (2022) · Figshare · doi:10.6084/m9.figshare.20317753
Metadata
- Authors
- Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., Algazi, A. P., Pampaloni, M. H., Lobach, I. V., Hwang, J., Pierce, R. H., Gratz, I. K., Krummel, M. F., & Rosenblum, M. D.
- Affiliations
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of California, San Francisco (US)
- University of Salzburg (AT)
- Corresponding author
- Rosenblum, Michael D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2016-08-15
- Volume
- 126
- Issue
- 9
- Pages
- 3447-3452
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5004965
- OpenAlex
- W2512255557
- Cited by
- 525
- References
- 23
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 37 · 2023: 47 · 2022: 51 · 2021: 55 · 2020: 89 · 2019: 61 · 2018: 71 · 2017: 64 · 2016: 5
- FWCI
- 36.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- International Business Machines Corporation
- National Institutes of Health (1dp2ar068130-01)
- University of California, San Francisco
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (DP2-AR068130, R21AR066821, K08AR062064)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- metastatic melanoma, anti-PD-1 therapy, immune checkpoint blockade, tumor immune profiling, CD8+ T cell exhaustion, tumor-infiltrating lymphocytes, predictive biomarkers, treatment response prediction, progression-free survival, regulatory T cells
- MeSH terms
- Biopsy, Female, Flow Cytometry, Humans, Immune System, Lymphocyte Activation, Male, Melanoma, Neoplasm Metastasis, Phenotype, Skin Neoplasms, Cohort Studies, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Tumor Microenvironment, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.